Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01654354

Enrollment

104

Registered

2012-07-31

Start date

2012-07-31

Completion date

2013-12-31

Last updated

2014-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal CT

Keywords

Qualitative Evaluation of abdominal CT image using 4 point scale: Excellent(4)/ Good(3) / Fair(2) / Unacceptable(1)

Brief summary

Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) with Ultravist 370 INJ.(Iopromide 768.86mg) in abdominal CT

Interventions

DRUGNEOVIST 370 INJ.(Iopromide 768.86mg)

DRUGUltravist 370 INJ.(Iopromide 768.86mg)

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Aged 20 to 75 years old. * Subjects who need CT scan * Subjects who are willing to participate in the study and to write the informed consent form.

Exclusion criteria

* Subjects with severe hepatopathy whose AST or ALT ≥ 1,000 IU/L, Subjects with liver cirrhosis whose AST or ALT ≥ UNL(upper normal limit) X 3 * Severe disorder of thyroid gland * homocystinuria * pregnant or breastfeeding female subjects, or female subjects with childbearing potential who are not willing to use proper contraception methods * Participation in another clinical trial within 30days of enrollment into this study.

Design outcomes

Primary

Measure	Time frame	Description
imaging quality	end of study enrollment	Two readers evaluate image quality of the abdomen CT by four-points scale
Adverse reaction	immediate after CT scan	—

Secondary

Measure	Time frame	Description
SNR (signal to noise ratio) / CNR (contrast to noise ratio)	at the end or enrollment	ROI measurement at abdominal aorta and liver

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026